Yardley, Pennsylvania, United States, March 2025 – Jennifer Panagos has joined NewAmsterdam Pharma Corporation as Head of Talent Acquisition. In this role, she will lead talent acquisition strategies, employer branding, and HR business partnering, ensuring that the company attracts, develops, and retains top talent to advance groundbreaking treatments for cardiovascular disease and lipid-related conditions.
Before joining NewAmsterdam Pharma Corporation, Jennifer Panagos was Senior Director, HR Business Partner at Amicus Therapeutics, where she led HR operations for the US Commercial Team, R&D, and corporate functions. She played a key role in organizational development, executive coaching, diversity and inclusion, and employee relations.
Prior to that, she spent nearly four years at Firmenich, holding leadership roles such as Director of Global Talent and Human Resources Director. During her tenure, she focused on employer branding, talent strategy, and HR business partnering for R&D divisions across North America. She also led HR integration efforts for Firmenich’s acquisition of Agilex Fragrance Company.
Earlier in her career, Jennifer spent over a decade at Bristol-Myers Squibb, where she held roles such as Human Resources Lead, R&D and Talent Acquisition Specialist. She contributed significantly to global clinical operations, talent management, M&A integration, and HR transformation. She also played a key role in recruitment strategies and employee value proposition development.
She began her career in recruitment and talent acquisition at companies such as Joulé, Momentum Resource Solutions, and Management Recruiters of New Brunswick, where she gained deep expertise in sourcing, talent engagement, and workforce planning.
About NewAmsterdam Pharma Corporation
Founded in 2019, NewAmsterdam Pharma Corporation is a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for cardiometabolic diseases. The company is advancing a selective cholesteryl ester transfer protein (CETP) inhibitor as a treatment for patients with Atherosclerotic Cardiovascular Disease (ASCVD) and Familial Hypercholesterolemia (FH). With a strong commitment to scientific innovation and patient care, NewAmsterdam Pharma is working to improve outcomes for populations where existing lipid-lowering therapies are insufficient.
Read Also : Entering 2025, TA Leaders’ Success Built on More than Just Hiring, Says The Josh Bersin Company
People Analytics Teams Still Struggle to Deliver Business Impact, Warns The Josh Bersin Company
ESG and Women’s Leadership: Driving Sustainability and Inclusion
Learning and Development Trends for 2025: Shaping the Future of Workplace Learning
